We have an updated report [Version - 2023] available. Kindly sign up to get the sample of the report.

Global Intravenous (IV) Iron Drugs Market: Analysis By Therapeutic Application, By Product Type, By Region, By Country (2018 Edition): Forecast to 2022 

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.


Executive Summary

A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Global I.V. Iron Drugs Market by Therapeutic Application (Nephrology, Gynecology & Obstetrics, Gastroenterology, Oncology, Cardiology, Others), By Product Type (Ferric carboxymaltose, Iron Sucrose, Iron Dextran and Others) for the regions (North America, Europe, Asia—Pacific and ROW) and By Country (U.S., Canada, U.K., Germany, France, China, India, Japan, Brazil, South Africa).

Over the recent years, the global Intravenous (IV) Iron Drug industry has been driven by the rising high prevalence of Iron Deficiency with unfulfilled need, rising awareness, growing prevalence of diseases leading to severe Iron Deficiency and increasing healthcare expenditure in emerging economies. Globally, the growth in IV Iron drug market is driven by growing middle class population group demanding better drugs to improve lifestyle.

According to Azoth Analytics research report, "Global Intravenous (IV) Iron Drugs Market: Analysis By Therapeutic Application (Nephrology, Gynecology & Obstetrics, Gastroenterology, Oncology, Cardiology, Others), By Product Type (Ferric Carboxymaltose, Iron Sucrose, Iron Dextran, Others) - By Region, By Country (2017-2022)", global market is projected to display a robust growth represented by a CAGR of 11.19% by value during 2017 - 2022, chiefly driven by increase in healthcare spending and rising prevalence of diseases with Iron deficiency, emerging second & third generation IV Iron drugs and growing middle class income group coupled with rising health consciousness.

Among the therapeutic application type, nephrology accounts for the major market share and anticipated to witness significant growth rate during the forecast period. Among the regions, Asia Pacific is predicted to advance at the highest rate, mainly driven by large population suffering with Iron Deficiency and unfulfilled need, improving access to healthcare, changing lifestyle and expanding middle class income group.

The report titled, "Global Intravenous (IV) Iron Drugs Market: Analysis By Therapeutic Application (Nephrology, Gynecology & Obstetrics, Gastroenterology, Oncology, Cardiology, Others), By Product Type (Ferric Carboxymaltose, Iron Sucrose, Iron Dextran, Others) - By Region, By Country (2017-2022)" has covered and analysed the potential of IV Iron Drug Market and provides statistics and information on market size, shares and growth factors. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment evaluation. Besides, the report also identifies and analyses the emerging trends along with major drivers, challenges and opportunities in the global IV Iron Drug market. Additionally, the report also highlights market entry strategies for various companies across the globe.


Scope of the Report

Global Market (Actual Period: 2012-2016, Forecast Period: 2017-2022)
• Global IV Iron Drug Market, By Value
• By Therapeutic Application (Nephrology, Gynecology & Obstetrics, Gastroenterology, Oncology, Cardiology, Others); By Value
• By Product Type (Ferric carboxymaltose, Iron Sucrose, Iron Dextran and Others), By Value

Regional Markets - North America, Europe, APAC, and ROW (Actual Period: 2012-2016, Forecast Period: 2017-2022)
• By Therapeutic Application (Nephrology, Gynecology & Obstetrics, Gastroenterology, Oncology, Cardiology, Others); By Value
• By Product Type (Ferric carboxymaltose, Iron Sucrose, Iron Dextran and Others), By Value

Country Analysis - United States, Canada, United Kingdom, Germany, France, China, India, Japan, Brazil and South Africa (Actual Period: 2012-2016, Forecast Period: 2017-2022)
• By Therapeutic Application (Nephrology, Gynecology & Obstetrics, Gastroenterology, Oncology, Cardiology, Others); By Value
• By Product Type (Ferric carboxymaltose, Iron Sucrose, Iron Dextran and Others), By Value

Other Report Highlights
• Market Dynamics - Trends, Drivers, Challenges, Policy and Regulation
• Company Analysis - Galenica; AMAG Pharmaceuticals, Inc; PHARMACOSMOS A/S; Allergan PLC; DAIICHI SANKYO COMPANY, LIMITED; NIPPON SHINYAKU CO., LTD and Sanofi


Customization of the Report
The report could be customized according to the client's specific research requirements. No additional cost will be required to pay for limited additional research.


Table of Contents

1. Research Methodology

2. Executive Summary

3. Strategic Recommendations
3.1. Asia Pacific Region to witness the fastest growth for I.V. Iron drug in the forecast period
3.2. Oncology & cardiology segments are witnessing fastest growth

4. I.V. Iron Drug Market Outlook

5. Global I.V. Iron Drug Market: Growth and Forecast

5.1. I.V. Iron Drug Market, By Value (2012-2016)
5.2. I.V. Iron Drug Market, By Value (2017-2022)
5.3. Global I.V. Iron Drug & Market - By Therapeutic Application, By Value
5.3.1. I.V. Iron Drug, By Value, % (2016)
5.3.2. I.V. Iron Drug, By Value, % (Forecast 2022F)
5.4. Global I.V. Iron Drug & Market- By Therapeutic Application, By Value (2012-2022)
5.4.1. Nephrology, By Value (2012-2022)
5.4.2. Gynecology & Obstetrics, By Value (2012-2022)
5.4.3. Gastroenterology, By Value (2012-2022)
5.4.4. Oncology, By Value (2012-2022)
5.4.5. Cardiology, By Value (2012-2022)
5.4.6. Others, By Value (2012-2022)
5.5. North America I.V. Iron Drug Market- By Product Type, By Value, (2012-2022)
5.5.1. Ferric carboxymaltose, By Value (2012-2022)
5.5.2. Iron Sucrose, By Value (2012-2022)
5.5.3. Iron Dextran
5.5.4. Others

6. North America I.V. Iron Drug Market: Growth and Forecast

6.1. North America I.V. Iron Drug Market, By Value (2012-2016)
6.2. North America I.V. Iron Drug Market, By Value (2017-2022)
6.3. North America I.V. Iron Drug & Market - By Therapeutic Application, By Value
6.3.1. I.V. Iron Drug, By Value, % (2016)
6.3.2. I.V. Iron Drug, By Value, % (Forecast 2022F)
6.4. North America I.V. Iron Drug & Market- By Therapeutic Application, By Value (2012-2022)
6.4.1. Nephrology, By Value (2012-2022)
6.4.2. Gynecology & Obstetrics, By Value (2012-2022)
6.4.3. Gastroenterology, By Value (2012-2022)
6.4.4. Oncology, By Value (2012-2022)
6.4.5. Cardiology, By Value (2012-2022)
6.4.6. Others, By Value (2012-2022)
6.5. North America I.V. Iron Drug Market- By Product Type, By Value, (2012-2022)
6.5.1. Ferric carboxymaltose, By Value (2012-2022)
6.5.2. Iron Sucrose, By Value (2012-2022)
6.5.3. Iron Dextran
6.5.4. Others
6.6. North America I.V. Iron Drug Market: Country Analysis (U.S., Canada)
6.6.1. North America I.V. Iron Drug Market, Country Share, 2012-2016 (% of Total)
6.6.2. North America I.V. Iron Drug Market, Country Share, 2017-2022 (% of Total)

6.7. U.S. I.V. Iron Drug Market: Growth and Forecast

6.7.1. U.S. I.V. Iron Drug Market, By Value (2012-2016)
6.7.2. U.S. I.V. Iron Drug Market, By Value (2017-2022)
6.8. U.S. I.V. Iron Drug & Market - By Therapeutic Application, By Value
6.8.1. I.V. Iron Drug, By Value, % (2016)
6.8.2. I.V. Iron Drug, By Value, % (Forecast 2022F)
6.9. U.S. I.V. Iron Drug & Market- By Therapeutic Application, By Value (2012-2022)
6.9.1. Nephrology, By Value (2012-2022)
6.9.2. Gynecology & Obstetrics, By Value (2012-2022)
6.9.3. Gastroenterology, By Value (2012-2022)
6.9.4. Oncology, By Value (2012-2022)
6.9.5. Cardiology, By Value (2012-2022)
6.9.6. Others, By Value (2012-2022)

6.10. Canada I.V. Iron Drug Market: Growth and Forecast

6.10.1. Canada I.V. Iron Drug Market, By Value (2012-2016)
6.10.2. Canada I.V. Iron Drug Market, By Value (2017-2022)
6.11. Canada I.V. Iron Drug & Market - By Therapeutic Application, By Value
6.11.1. I.V. Iron Drug, By Value, % (2016)
6.11.2. I.V. Iron Drug, By Value, % (Forecast 2022F)
6.12. Canada I.V. Iron Drug & Market- By Therapeutic Application, By Value (2012-2022)
6.12.1. Nephrology, By Value (2012-2022)
6.12.2. Gynecology & Obstetrics, By Value (2012-2022)
6.12.3. Gastroenterology, By Value (2012-2022)
6.12.4. Oncology, By Value (2012-2022)
6.12.5. Cardiology, By Value (2012-2022)
6.12.6. Others, By Value (2012-2022)

7. Europe I.V. Iron Drug Market: Growth and Forecast

7.1. I.V. Iron Drug Market, By Value (2012-2016)
7.2. I.V. Iron Drug Market, By Value (2017-2022)
7.3. Europe I.V. Iron Drug & Market - By Therapeutic Application, By Value
7.3.1. I.V. Iron Drug, By Value, % (2016)
7.3.2. I.V. Iron Drug, By Value, % (Forecast 2022F)
7.4. Europe I.V. Iron Drug & Market- By Therapeutic Application, By Value (2012-2022)
7.4.1. Nephrology, By Value (2012-2022)
7.4.2. Gynecology & Obstetrics, By Value (2012-2022)
7.4.3. Gastroenterology, By Value (2012-2022)
7.4.4. Oncology, By Value (2012-2022)
7.4.5. Cardiology, By Value (2012-2022)
7.4.6. Others, By Value (2012-2022)
7.5. Europe I.V. Iron Drug Market- By Product Type, By Value, (2012-2022)
7.5.1. Ferric carboxymaltose, By Value (2012-2022)
7.5.2. Iron Sucrose, By Value (2012-2022)
7.5.3. Iron Dextran
7.5.4. Others
7.6. Europe I.V. Iron Drug Market: Country Analysis (U.K., Germany, France, Rest of Europe)
7.6.1. Europe I.V. Iron Drug Market, Country Share, 2012-2016 (% of Total)
7.6.2. Europe I.V. Iron Drug Market, Country Share, 2017-2022 (% of Total)

7.7. U.K. I.V. Iron Drug Market: Growth and Forecast

7.7.1. U.K. I.V. Iron Drug Market, By Value (2012-2016)
7.7.2. U.K. I.V. Iron Drug Market, By Value (2017-2022)
7.8. U.K. I.V. Iron Drug & Market - By Therapeutic Application, By Value
7.8.1. I.V. Iron Drug, By Value, % (2016)
7.8.2. I.V. Iron Drug, By Value, % (Forecast 2022F)
7.9. U.K. I.V. Iron Drug & Market- By Therapeutic Application, By Value (2012-2022)
7.9.1. Nephrology, By Value (2012-2022)
7.9.2. Gynecology & Obstetrics, By Value (2012-2022)
7.9.3. Gastroenterology, By Value (2012-2022)
7.9.4. Oncology, By Value (2012-2022)
7.9.5. Cardiology, By Value (2012-2022)
7.9.6. Others, By Value (2012-2022)

7.10. Germany I.V. Iron Drug Market: Growth and Forecast

7.10.1. Germany I.V. Iron Drug Market, By Value (2012-2016)
7.10.2. Germany I.V. Iron Drug Market, By Value (2017-2022)
7.11. Germany I.V. Iron Drug & Market - By Therapeutic Application, By Value
7.11.1. I.V. Iron Drug, By Value, % (2016)
7.11.2  I.V. Iron Drug, By Value, % (Forecast 2022F)
7.12. Germany I.V. Iron Drug & Market- By Therapeutic Application, By Value (2012-2022) 
7.12.1. Nephrology, By Value (2012-2022)
7.12.2. Gynecology & Obstetrics, By Value (2012-2022)
7.12.3. Gastroenterology, By Value (2012-2022)
7.12.4. Oncology, By Value (2012-2022)
7.12.5. Cardiology, By Value (2012-2022)
7.12.6. Others, By Value (2012-2022)

7.13. France I.V. Iron Drug Market: Growth and Forecast

7.13.1. France I.V. Iron Drug Market, By Value (2012-2016)
7.13.2. France I.V. Iron Drug Market, By Value (2017-2022)
7.14. France I.V. Iron Drug & Market - By Therapeutic Application, By Value
7.14.1. I.V. Iron Drug, By Value, % (2016)
7.14.2. I.V. Iron Drug, By Value, % (Forecast 2022F)
7.15. France I.V. Iron Drug & Market- By Therapeutic Application, By Value (2012-2022)
7.15.1. Nephrology, By Value (2012-2022)
7.15.2. Gynecology & Obstetrics, By Value (2012-2022)
7.15.3. Gastroenterology, By Value (2012-2022)
7.15.4. Oncology, By Value (2012-2022)
7.15.5. Cardiology, By Value (2012-2022)
7.15.6. Others, By Value (2012-2022)

7.16. Rest of Europe I.V. Iron Drug Market: Growth and Forecast
7.16.1. Rest of Europe I.V. Iron Drug Market, By Value (2012-2016)
7.16.2. Rest of Europe I.V. Iron Drug Market, By Value (2017-2022)

8. Asia Pacific I.V. Iron Drug Market: Growth and Forecast

8.1. I.V. Iron Drug Market, By Value (2012-2016)
8.2. I.V. Iron Drug Market, By Value (2017-2022)
8.3. Asia Pacific I.V. Iron Drug & Market - By Therapeutic Application, By Value
8.3.1. I.V. Iron Drug, By Value, % (2016)
8.3.2. I.V. Iron Drug, By Value, % (Forecast 2022F)
8.4. Asia Pacific I.V. Iron Drug & Market- By Therapeutic Application, By Value (2012-2022)
8.4.1. Nephrology, By Value (2012-2022)
8.4.2. Gynecology & Obstetrics, By Value (2012-2022)
8.4.3. Gastroenterology, By Value (2012-2022)
8.4.4. Oncology, By Value (2012-2022)
8.4.5. Cardiology, By Value (2012-2022)
8.4.6. Others, By Value (2012-2022)
8.5. Asia Pacific I.V. Iron Drug Market- By Product Type, By Value, (2012-2022)
8.5.1. Ferric carboxymaltose, By Value (2012-2022)
8.5.2. Iron Sucrose, By Value (2012-2022)
8.5.3. Iron Dextran
8.5.4. Others
8.6. Asia Pacific I.V. Iron Drug Market: Country Analysis (Japan, China, India, Rest of Asia-Pacific)
8.6.1. Asia Pacific I.V. Iron Drug Market, Country Share, 2012-2016 (% of Total)
8.6.2. Asia Pacific I.V. Iron Drug Market, Country Share, 2017-2022 (% of Total)

8.7. Japan I.V. Iron Drug Market: Growth and Forecast

8.7.1. Japan I.V. Iron Drug Market, By Value (2012-2016)
8.7.2. Japan I.V. Iron Drug Market, By Value (2017-2022)
8.8. Japan I.V. Iron Drug & Market - By Therapeutic Application, By Value
8.8.1. I.V. Iron Drug, By Value, % (2016)
8.8.2. I.V. Iron Drug, By Value, % (Forecast 2022F)
8.9. Japan I.V. Iron Drug & Market- By Therapeutic Application, By Value (2012-2022)
8.9.1. Nephrology, By Value (2012-2022)
8.9.2. Gynecology & Obstetrics, By Value (2012-2022)
8.9.3. Gastroenterology, By Value (2012-2022)
8.9.4. Oncology, By Value (2012-2022)
8.9.5. Cardiology, By Value (2012-2022)
8.9.6. Others, By Value (2012-2022)

8.10. China I.V. Iron Drug Market: Growth and Forecast

8.10.1. China I.V. Iron Drug Market, By Value (2012-2016)
8.10.2. China I.V. Iron Drug Market, By Value (2017-2022)
8.11. China I.V. Iron Drug & Market - By Therapeutic Application, By Value
8.11.1. I.V. Iron Drug, By Value, % (2016)
8.11.2. I.V. Iron Drug, By Value, % (Forecast 2022F)
8.12. China I.V. Iron Drug & Market- By Therapeutic Application, By Value (2012-2022)
8.12.1. Nephrology, By Value (2012-2022)
8.12.2. Gynecology & Obstetrics, By Value (2012-2022)
8.12.3. Gastroenterology, By Value (2012-2022)
8.12.4. Oncology, By Value (2012-2022)
8.12.5. Cardiology, By Value (2012-2022)
8.12.6. Others, By Value (2012-2022)

8.13. India I.V. Iron Drug Market: Growth and Forecast

8.13.1. India I.V. Iron Drug Market, By Value (2012-2016)
8.13.2. India I.V. Iron Drug Market, By Value (2017-2022)
8.14. India I.V. Iron Drug & Market - By Therapeutic Application, By Value
8.14.1. I.V. Iron Drug, By Value, % (2016)
8.14.2. I.V. Iron Drug, By Value, % (Forecast 2022F)
8.15. India I.V. Iron Drug & Market- By Therapeutic Application, By Value (2012-2022)
8.15.1. Nephrology, By Value (2012-2022)
8.15.2. Gynecology & Obstetrics, By Value (2012-2022)
8.15.3. Gastroenterology, By Value (2012-2022)
8.15.4. Oncology, By Value (2012-2022)
8.15.5. Cardiology, By Value (2012-2022)
8.15.6. Others, By Value (2012-2022)

8.16. Rest of Asia Pacific I.V. Iron Drug Market: Growth and Forecast
8.16.1. Rest of Asia Pacific I.V. Iron Drug Market, By Value (2012-2016)
8.16.2. Rest of Asia Pacific I.V. Iron Drug Market, By Value (2017-2022)

9. ROW I.V. Iron Drug Market: Growth and Forecast
9.1. I.V. Iron Drug Market, By Value (2012-2016)
9.2. I.V. Iron Drug Market, By Value (2017-2022)
9.3. ROW I.V. Iron Drug & Market - By Therapeutic Application, By Value
9.3.1. I.V. Iron Drug, By Value, % (2016)
9.3.2. I.V. Iron Drug, By Value, % (Forecast 2022F)
9.4. ROW I.V. Iron Drug & Market- By Therapeutic Application, By Value (2012-2022)
9.4.1. Nephrology, By Value (2012-2022)
9.4.2. Gynecology & Obstetrics, By Value (2012-2022)
9.4.3. Gastroenterology, By Value (2012-2022)
9.4.4. Oncology, By Value (2012-2022)
9.4.5. Cardiology, By Value (2012-2022)
9.4.6. Others, By Value (2012-2022)
9.5. ROW I.V. Iron Drug Market- By Product Type, By Value, (2012-2022)
9.5.1. Ferric carboxymaltose, By Value (2012-2022)
9.5.2. Iron Sucrose, By Value (2012-2022)
9.5.3. Iron Dextran
9.5.4. Others

9.6. ROW I.V. Iron Drug Market: Country Analysis (Brazil, South Africa)
9.6.1. ROW I.V. Iron Drug Market, Country Share, 2012-2016 (% of Total)
9.6.2. ROW I.V. Iron Drug Market, Country Share, 2017-2022 (% of Total)

9.7. Brazil I.V. Iron Drug Market: Growth and Forecast
9.7.1. Brazil I.V. Iron Drug Market, By Value (2012-2016)
9.7.2. Brazil I.V. Iron Drug Market, By Value (2017-2022)

9.8. South Africa I.V. Iron Drug Market: Growth and Forecast
9.8.1. South Africa I.V. Iron Drug Market, By Value (2012-2016)
9.8.2. South Africa I.V. Iron Drug Market, By Value (2017-2022)

10. Market Dynamics       
10.1. Increasing Geriatric Population Worldwide
10.2. Increasing awareness about the Iron Deficiency diseases
10.3. Rising healthcare expenditure worldwide
10.4. Increasing number of dialysis patients
10.5. Increasing Life Expectancy

11. Market Restraints

12. SWOT Analysis - I.V. Iron Drug Market     
                                                                              
13. Porter's Five Forces Analysis - I.V. Iron Drug Market 
                                                                                          
14. Policy and Regulations

15. Company Profiles
15.1. Galenica
15.2. AMAG Pharmaceuticals, Inc 
15.3. PHARMACOSMOS A/S
15.4. Allergan PLC
15.5. Daichi Sankyo Company Ltd.  
15.6. Nippon Shinyaku Co. Ltd.  
15.7. Sanofi 

16. About Us

Choose License Type

Happy To Assist You

Contact Images

We will be happy to help you find what you need. Please call us or write to us:

Frequently Asked Questions

This report incorporates the analysis of factors that augments the market growth. Report presents competitive landscape of the global market. This also provides the scope of different segments and applications that can potentially influence the market in the future. The analysis is based on current market trends and historic growth data. It includes detailed market segmentation, regional analysis, and competitive landscape of the industry.
The report efficiently evaluates the current market size and provides industry forecast. The market was valued at xxx Million US$ in 2019, and is expected to grow at a CAGR of xx% during the period 2020-2027.
The report efficiently evaluates the current market size and provides forecast for the industry in terms of Value (US$ Mn) and Volume (Thousands Units).
Market is segmented by:
  • Product Types
  • Drug Class
  • Indication
  • Applications
  • Services Types
  • End-users
  • Distribution channel
  • Regions
The report share key insights on the following:
  • Current market size
  • Market forecast
  • Market opportunities
  • Key drivers
  • Restraints
  • Pipeline Analysis
  • Incidence Rate
  • Epidemiology Analysis
  • Prevalence rate
  • Regulatory scenario
  • Industry trend
  • Pestle Analysis
  • Porter’s Analysis
  • New product approvals/launch
  • Promotion and marketing initiatives
  • Pricing analysis
  • Export-import analysis
  • Trade analysis
  • Competitive landscape
It helps the businesses in making investments decisions.
Customization helps the organization to gain insight on specific segments and regions of interest. Thus, WMR offers tailored report information based on business requirement in order to take strategic calls.
Contact us

mapicon
Sales Office (U.S.):
Worldwide Market Reports, 533 Airport Boulevard, Suite 400, Burlingame, CA 94010, United States

mapicon+1-415-871-0703

mapicon
Asia Pacific Intelligence Center (India):
Worldwide Market Reports, 403, 4th Floor, Bremen Business Center, Aundh, Pune, Maharashtra 411007, India.

Newsletter

Want us to send you latest updates of the current trends, insights, and more, signup to our newsletter (for alerts, special offers, and discounts).


Secure Payment By:
paymenticon

This website is secured Origin CA certificate on the server, Comodo, Firewall and Verified Sitelock Malware Protection

secureimg

© 2024 Worldwide Market Reports. All Rights Reserved